Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa

BACKGROUND: Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson's disease (PD). This report evaluates long-term safety and efficacy of high-dose LCIG in PD patients. METHODS: Data were collected from seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zadikoff, Cindy, Poewe, Werner, Boyd, James T., Bergmann, Lars, Ijacu, Horia, Kukreja, Pavnit, Robieson, Weining Z., Benesh, Janet, Antonini, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040420/
https://www.ncbi.nlm.nih.gov/pubmed/32104560
http://dx.doi.org/10.1155/2020/9716317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040420/
https://www.ncbi.nlm.nih.gov/pubmed/32104560
http://dx.doi.org/10.1155/2020/9716317

Ejemplares similares